Heart failure & cardiomyopathies
Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review
Authors' conclusion
Multiple pharmacological options are potential disease-modifying therapies for ATTR-CM.
Study context
- Population
- Transthyretin amyloid cardiomyopathy (ATTR-CM)19 studies
Methodological detailsPRISMA guidelines
- PRISMA guidelines
Main finding
As reported in the abstract
- 19 studies included: 8 clinical trials, 11 observational analyses
- Drugs evaluated: tafamadis, acoramidis, revusiran, doxycycline and tauroursodeoxycholic acid, doxycycline, diflusinil, inotersan, eplontersen, patisiran
- Tafamidis efficacious in ATTR-CM, particularly when initiated at earlier stages
- RNA interference and antisense oligonucleotide drugs: promising impacts on quality of life
- Gaps in literature: long-term outcomes, comparative effectiveness, translation into economic contexts
Original publication
Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review. Eur Heart J Cardiovasc Pharmacother. Published 3 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →